WHO ICTRP trial
Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with…
EUCTR2008-000105-11-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-000105-11-DE |
|---|---|
| Public title | Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA - TAMARA - Tocilizumab And DMARDs: Achievements in Rheumatoid Arthritis |
| Scientific title | Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA - TAMARA - Tocilizumab And DMARDs: Achievements in Rheumatoid Arthritis |
| Primary sponsor | Roche Pharma AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis |
| Interventions | Trade Name: RoActemra Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit… |
| Registration date | May 16, 2008 |
| Secondary IDs | ML21469 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: